{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:35:14Z","timestamp":1778578514287,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/jnci\/djx255","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T15:18:00Z","timestamp":1510586280000},"page":"616-627","source":"Crossref","is-referenced-by-count":7,"title":["Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial"],"prefix":"10.1093","volume":"110","author":[{"given":"Antonia K","family":"Roseweir","sequence":"first","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"},{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Bennett","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"},{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Dickson","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Anne","family":"Quintayo","sequence":"additional","affiliation":[{"name":"Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Bayani","sequence":"additional","affiliation":[{"name":"Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald C","family":"McMillan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G","family":"Horgan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis J H","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Seynaeve","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[{"name":"University Hospital Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk G","family":"Kieback","sequence":"additional","affiliation":[{"name":"Helios Medical Centre, Schleswig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Markopoulos","sequence":"additional","affiliation":[{"name":"Athens University Medical School, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc Y","family":"Dirix","sequence":"additional","affiliation":[{"name":"St Augustinus Hospital, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel W","family":"Rea","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Mallon","sequence":"additional","affiliation":[{"name":"Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M S","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Ontario Institute of Cancer Research, MaRS Institute, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Edwards","sequence":"additional","affiliation":[{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"key\n\t\t\t\t20180618194126_djx255-B1","first-page":"849592","article-title":"Adjuvant hormonal therapy in postmenopausal women with breast cancer: Physician's choices","volume":"2012","author":"Shaikh","year":"2012","journal-title":"Int J Breast Cancer."},{"issue":"1","key":"key\n\t\t\t\t20180618194126_djx255-B2","first-page":"45","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex TAoiCTG","year":"2008","journal-title":"Lancet Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180618194126_djx255-B3","first-page":"486","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol."},{"issue":"9561","key":"key\n\t\t\t\t20180618194126_djx255-B4","first-page":"559","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet."},{"key":"key\n\t\t\t\t20180618194126_djx255-B5","author":"The national institute of health and care excellence (NICE)","year":"2009"},{"issue":"1","key":"key\n\t\t\t\t20180618194126_djx255-B6","first-page":"13","article-title":"The impact of the Oncotype Dx breast cancer assay in clinical practice: A systematic review and meta-analysis","volume":"141","author":"Carlson","year":"2013","journal-title":"Breast Cancer Res Treat."},{"issue":"16","key":"key\n\t\t\t\t20180618194126_djx255-B7","first-page":"4465","article-title":"A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen","volume":"18","author":"Chia","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"8","key":"key\n\t\t\t\t20180618194126_djx255-B8","first-page":"967","article-title":"The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone","volume":"115","author":"Campbell","year":"2016","journal-title":"Br J Cancer."},{"issue":"9762","key":"key\n\t\t\t\t20180618194126_djx255-B9","first-page":"321","article-title":"Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial","volume":"377","author":"van de Velde","year":"2011","journal-title":"Lancet."},{"issue":"4","key":"key\n\t\t\t\t20180618194126_djx255-B10","first-page":"1487","article-title":"Ras\/Raf-1\/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients","volume":"15","author":"McGlynn","year":"2009","journal-title":"Clin Cancer Res."},{"issue":"7","key":"key\n\t\t\t\t20180618194126_djx255-B11","first-page":"1633","article-title":"High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer","volume":"140","author":"Bennett","year":"2017","journal-title":"Int J Cancer."},{"issue":"5","key":"key\n\t\t\t\t20180618194126_djx255-B12","first-page":"782","article-title":"The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer","volume":"70","author":"Cheng","year":"2017","journal-title":"Histopathology."},{"issue":"1","key":"key\n\t\t\t\t20180618194126_djx255-B13","first-page":"R1","article-title":"Clinical significance of estrogen receptor phosphorylation","volume":"18","author":"Murphy","year":"2011","journal-title":"Endocr Relat Cancer."},{"issue":"12","key":"key\n\t\t\t\t20180618194126_djx255-B14","first-page":"1531","article-title":"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: A prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial","volume":"29","author":"Bartlett","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"key\n\t\t\t\t20180618194126_djx255-B15","first-page":"387","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer."},{"issue":"1","key":"key\n\t\t\t\t20180618194126_djx255-B16","first-page":"71","article-title":"Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation","volume":"18","author":"Park","year":"2005","journal-title":"Mol Cell."},{"issue":"1","key":"key\n\t\t\t\t20180618194126_djx255-B17","first-page":"1","article-title":"Estrogen receptor phosphorylation","volume":"68","author":"Lannigan","year":"2003","journal-title":"Steroids."},{"issue":"7381","key":"key\n\t\t\t\t20180618194126_djx255-B18","first-page":"389","article-title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","volume":"481","author":"Ross-Innes","year":"2012","journal-title":"Nature."},{"issue":"10","key":"key\n\t\t\t\t20180618194126_djx255-B19","first-page":"7920","article-title":"A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells","volume":"277","author":"Dhawan","year":"2002","journal-title":"J Biol Chem."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/110\/6\/616\/25041899\/djx255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:43:49Z","timestamp":1529351029000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/110\/6\/616\/4780394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,27]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djx255","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2017,12,27]]}}}